Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Overcoming target‐driven fratricide for CAR‐T cell therapy

Overcoming target‐driven fratricide for CAR‐T cell therapy

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs

Differential effects of target ligands upon NKG2D CAR T cell activation

Differential effects of target ligands upon NKG2D CAR T cell activation

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells

Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer

The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer

Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy

Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy